Catalyst Orthoscience
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$2.8Mgeneral payments (2019-2025)
$0.00research payments (2019-2025)
762clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Catalyst Csr Shoulder System $619K associated (2023-2025)
- R1 Reverse Shoulder System $569K associated (2023-2025)
- Catalyst Total Csr $485K associated (2023-2025)
- R1 Reverse Total Shoulder $42K associated (2023-2025)
- Csr & R1 Reverse Total Shoulder Systems $39K associated (2023-2025)
- Archer 3d Software $37K associated (2023-2025)
- Catalyst Fracture Shoulder System $28K associated (2023-2025)
- Archer Csr Total Shoulder System $2,963 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Zachary Leitze | St George, UT | Orthopaedic Surgery | $762,245.84 |
| Theodore Blaine | New York, NY | Sports Medicine (Orthopaedic Surgery) | $681,732.12 |
| Steven Goldberg | Naples, FL | Orthopaedic Surgery | $130,409.57 |
| John Costouros | Redwood City, CA | Orthopaedic Surgery | $77,388.18 |
| Aaron Bare | Warrenville, IL | Orthopaedic Surgery | $64,746.65 |
| Nicholas Capito | Augusta, GA | Orthopaedic Surgery | $63,347.43 |
| Edward Paxton | Providence, RI | Orthopaedic Surgery | $62,836.95 |
| Ira Parsons | Somersworth, NH | Orthopaedic Surgery | $59,856.43 |
| Matthew Budge | Las Vegas, NV | Orthopaedic Surgery | $56,211.40 |
| Caroline Chebli | Sarasota, FL | Orthopaedic Surgery | $51,076.55 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.